{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:06:13Z","timestamp":1777529173617,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12272-013-0297-x","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T05:37:06Z","timestamp":1384839426000},"page":"1560-1569","source":"Crossref","is-referenced-by-count":9,"title":["Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats"],"prefix":"10.1007","volume":"37","author":[{"given":"Jin Woo","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"297_CR1","first-page":"233","volume":"67","author":"B Bittner","year":"2012","unstructured":"Bittner, B., C. McIntyre, H. Tian, K. Tang, N. Shah, W. Phuapradit, H. Ahmed, H. Chokshi, M. Infeld, N. Fotaki, H. Ma, A. Portron, P. Jordan, and J. Schmidt. 2012. Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Pharmazie 67: 233\u2013241.","journal-title":"Pharmazie"},{"key":"297_CR2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1345\/aph.1L555","volume":"43","author":"WA Blumentals","year":"2009","unstructured":"Blumentals, W.A., S.T. Harris, R.E. Cole, L. Huang, and S.L. Silverman. 2009. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Annals of Pharmacotherapy 43: 577\u2013585.","journal-title":"Annals of Pharmacotherapy"},{"key":"297_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","volume":"6","author":"FP Coxon","year":"2006","unstructured":"Coxon, F.P., K. Thompson, and M.J. Rogers. 2006. Recent advances in understanding the mechanism of action of bisphosphonates. Current Opinion in Pharmacology 6: 307\u2013312.","journal-title":"Current Opinion in Pharmacology"},{"key":"297_CR4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer, J.A., M.M. Amonkar, A. Hebborn, and R. Altman. 2005. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Medical Research and Opinion 21: 1453\u20131460.","journal-title":"Current Medical Research and Opinion"},{"key":"297_CR5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","volume":"42","author":"PD Delmas","year":"2008","unstructured":"Delmas, P.D., M.R. McClung, J.R. Zanchetta, A. Racewicz, C. Roux, C.L. Benhamou, Z. Man, R.A. Eusebio, J.F. Beary, D.E. Burgio, E. Matzkin, and S. Boonen. 2008. Efficacy and safety of risedronate 150\u00a0mg once a month in the treatment of postmenopausal osteoporosis. Bone 42: 36\u201342.","journal-title":"Bone"},{"key":"297_CR6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00003495-200161050-00013","volume":"61","author":"CJ Dunn","year":"2001","unstructured":"Dunn, C.J., and K.L. Goa. 2001. Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 61: 685\u2013712.","journal-title":"Drugs"},{"key":"297_CR7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell, R., I. Barton, R.A. Hannon, A. Chines, P. Garnero, and P.D. Delmas. 2003. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of Bone and Mineral Research 18: 1051\u20131056.","journal-title":"Journal of Bone and Mineral Research"},{"key":"297_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","volume":"31","author":"EF Eriksen","year":"2002","unstructured":"Eriksen, E.F., F. Melsen, E. Sod, I. Barton, and A. Chines. 2002. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31: 620\u2013625.","journal-title":"Bone"},{"key":"297_CR9","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1021\/jm980645y","volume":"43","author":"A Ezra","year":"2000","unstructured":"Ezra, A., A. Hoffman, E. Breuer, I.S. Alferiev, J. M\u00f6nkk\u00f6nen, N. El Hanany-Rozen, G. Weiss, D. Stepensky, I. Gati, H. Cohen, S. T\u00f6rm\u00e4lehto, G.L. Amidon, and G. Golomb. 2000. A peptide prodrug approach for improving bisphosphonate oral absorption. Journal of Medicinal Chemistry 43: 3641\u20133652.","journal-title":"Journal of Medicinal Chemistry"},{"key":"297_CR10","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji, P., J.R. Zanchetta, L. Russo, C.P. Recknor, K.G. Saag, F.E. McKiernan, S.L. Silverman, J. Alam, R.T. Burge, J.H. Krege, M.C. Lakshmanan, D.N. Masica, B.H. Mitlak, and J.L. Stock. 2012. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis International 23: 2141\u20132150.","journal-title":"Osteoporosis International"},{"key":"297_CR11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","volume":"14","author":"B Hamilton","year":"2003","unstructured":"Hamilton, B., K. McCoy, and H. Taggart. 2003. Tolerability and compliance with risedronate in clinical practice. Osteoporosis International 14: 259\u2013262.","journal-title":"Osteoporosis International"},{"key":"297_CR12","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1021\/jm7015792","volume":"51","author":"AM Hounslow","year":"2008","unstructured":"Hounslow, A.M., J. Carran, R.J. Brown, D. Rejman, M. Blackburn, and D.J. Watts. 2008. Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs. Journal of Medicinal Chemistry 51: 4170\u20134178.","journal-title":"Journal of Medicinal Chemistry"},{"key":"297_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/13697130600652180","volume":"9","author":"E Ilter","year":"2006","unstructured":"Ilter, E., H. Karalok, E.C. Tufekci, and O. Batur. 2006. Efficacy and acceptability of risedronate 5\u00a0mg daily compared with 35\u00a0mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric 9: 129\u2013134.","journal-title":"Climacteric"},{"key":"297_CR14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF02556218","volume":"49","author":"M Janner","year":"1991","unstructured":"Janner, M., R.C. M\u00fchlbauer, and H. Fleisch. 1991. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcified Tissue International 49: 280\u20132803.","journal-title":"Calcified Tissue International"},{"key":"297_CR15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11095-012-0932-0","volume":"30","author":"OC Jeon","year":"2013","unstructured":"Jeon, O.C., S.R. Hwang, T.A. Al-Hilal, J.W. Park, H.T. Moon, S. Lee, J.H. Park, and Y. Byun. 2013. Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates. Pharmaceutical Research 30: 959\u2013967.","journal-title":"Pharmaceutical Research"},{"key":"297_CR16","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","volume":"16","author":"KL Kavanagh","year":"2006","unstructured":"Kavanagh, K.L., K. Guo, J.E. Dunford, X. Wu, S. Knapp, F.H. Ebetino, M.J. Rogers, R.G. Russell, and U. Oppermann. 2006. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proceedings of the National Academy of Sciences of the United States of America 16: 7829\u20137834.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"297_CR17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jpba.2005.06.014","volume":"39","author":"SK Kim","year":"2005","unstructured":"Kim, S.K., K. Kim, S. Lee, K. Park, J.H. Park, I.C. Kwon, K. Choi, C.Y. Kim, and Y. Byun. 2005. Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface Plasmon resonance. Journal of Pharmaceutical and Biomedical Analysis 39: 861\u2013870.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"297_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2007.03.008","volume":"120","author":"SK Kim","year":"2007","unstructured":"Kim, S.K., D.Y. Lee, E. Lee, Y.K. Lee, C.Y. Kim, H.T. Moon, and Y. Byun. 2007. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anticoagulant. Journal of Control Release 120: 4\u201310.","journal-title":"Journal of Control Release"},{"key":"297_CR19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/mp9002688","volume":"7","author":"SK Kim","year":"2010","unstructured":"Kim, S.K., S. Lee, S. Jin, H.T. Moon, O.C. Jeon, D.Y. Lee, and Y. Byun. 2010. Diabetes correction in pancreatectomized canines by orally absorbable insulin-deoxycholate complex. Molecular Pharmaceutics 7: 708\u2013717.","journal-title":"Molecular Pharmaceutics"},{"key":"297_CR20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","volume":"86","author":"DB Kimmel","year":"2007","unstructured":"Kimmel, D.B. 2007. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. Journal of Dental Research 86: 1022\u20131033.","journal-title":"Journal of Dental Research"},{"key":"297_CR21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1196\/annals.1365.036","volume":"1092","author":"I Lambrinoudaki","year":"2006","unstructured":"Lambrinoudaki, I., G. Christodoulakos, and D. Botsis. 2006. Bisphosphonates. Annals of the New York Academy of Sciences 1092: 397\u2013402.","journal-title":"Annals of the New York Academy of Sciences"},{"key":"297_CR22","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.50.5.1869-1871.2006","volume":"50","author":"S Lee","year":"2006","unstructured":"Lee, S., S.K. Kim, D.Y. Lee, S.Y. Chae, and Y. Byun. 2006. Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats. Antimicrobial Agents and Chemotherapy 50: 1869\u20131871.","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"297_CR23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00125-004-1658-2","volume":"48","author":"S Lee","year":"2005","unstructured":"Lee, S., J. Lee, D.Y. Lee, S.K. Kim, Y. Lee, and Y. Byun. 2005. A new drug carrier, N-alpha-deoxycholyl-l-lysyl-methylester, for enhancing insulin absorption in the intestine. Diabetologia 48: 405\u2013411.","journal-title":"Diabetologia"},{"key":"297_CR24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin, J.H. 1996. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75\u201385.","journal-title":"Bone"},{"key":"297_CR25","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/jps.2600831218","volume":"83","author":"JH Lin","year":"1994","unstructured":"Lin, J.H., I.W. Chen, and F.A. deLuna. 1994. On the absorption of alendronate in rats. Journal of Pharmaceutical Sciences 83: 1741\u20131746.","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"297_CR26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0090-9556(25)08972-X","volume":"19","author":"JH Lin","year":"1991","unstructured":"Lin, J.H., D.E. Duggan, I.W. Chen, and R.L. Ellsworth. 1991. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metabolism and Disposition 19: 926\u2013932.","journal-title":"Drug Metabolism and Disposition"},{"key":"297_CR27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman, S.P., D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 13: 581\u2013589.","journal-title":"Journal of Bone and Mineral Research"},{"key":"297_CR28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00223-012-9668-4","volume":"92","author":"MR McClung","year":"2013","unstructured":"McClung, M.R., C.L. Benhamou, Z. Man, W. Tlustochowicz, J.R. Zanchetta, R. Eusebio, A.M. Balske, E. Matzkin, W.P. Olszynski, R. Recker, and P.D. Delmas. 2013. A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcified Tissue International 92: 59\u201367.","journal-title":"Calcified Tissue International"},{"key":"297_CR29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1023\/A:1011024200280","volume":"18","author":"DY Mitchell","year":"2001","unstructured":"Mitchell, D.Y., W.H. Barr, R.A. Eusebio, K.A. Stevens, F.P. Duke, D.A. Russell, J.D. Nesbitt, J.H. Powell, and G.A. Thompson. 2001. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharmaceutical Research 18: 166\u2013170.","journal-title":"Pharmaceutical Research"},{"key":"297_CR30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/00912700022008928","volume":"40","author":"DY Mitchell","year":"2000","unstructured":"Mitchell, D.Y., R.A. Eusebio, N.A. Sacco-Gibson, K.A. Pallone, S.C. Kelly, J.D. Nesbitt, C.P. Brezovic, G.A. Thompson, and J.H. Powell. 2000. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. Journal of Clinical Pharmacology 40: 258\u2013265.","journal-title":"Journal of Clinical Pharmacology"},{"key":"297_CR31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2125.1999.00035.x","volume":"48","author":"DY Mitchell","year":"1999","unstructured":"Mitchell, D.Y., M.A. Heise, K.A. Pallone, M.E. Clay, J.D. Nesbitt, D.A. Russell, and C.W. Melson. 1999. The effect of dosing regimen on the pharmacokinetics of risedronate. British Journal of Clinical Pharmacology 48: 536\u2013542.","journal-title":"British Journal of Clinical Pharmacology"},{"key":"297_CR32","first-page":"396","volume":"83","author":"L Mortensen","year":"1998","unstructured":"Mortensen, L., P. Charles, P.J. Bekker, J. Digennaro, and C.C. Johnston Jr. 1998. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus 1\u00a0year of follow-up. Journal of Clinical Endocrinology and Metabolism 83: 396\u2013402.","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"297_CR33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2011.10.017","volume":"50","author":"SH Nam","year":"2012","unstructured":"Nam, S.H., J.H. Jeong, X. Che, K.E. Lim, H. Nam, J.S. Park, and J.Y. Choi. 2012. Topically administered risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model. Bone 50: 149\u2013155.","journal-title":"Bone"},{"key":"297_CR34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jps.23413","volume":"102","author":"JW Park","year":"2013","unstructured":"Park, J.W., S.R. Hwang, O. Jeon, H.T. Moon, and Y. Byun. 2013. Enhanced oral absorption of ibandronate via complex formation with bile acid derivative. Journal of Pharmaceutical Sciences 102: 341\u2013346.","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"297_CR35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11914-003-0008-5","volume":"1","author":"AA Reszka","year":"2003","unstructured":"Reszka, A.A., and G.A. Rodan. 2003. Mechanism of action of bisphosphonates. Current Osteoporosis Reports 1: 45\u201352.","journal-title":"Current Osteoporosis Reports"},{"key":"297_CR36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan, G.A., and T.J. Martin. 2000. Therapeutic approaches to bone diseases. Science 289: 1508\u20131514.","journal-title":"Science"},{"key":"297_CR37","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","volume":"13","author":"ES Siris","year":"1998","unstructured":"Siris, E.S., A.A. Chines, R.D. Altman, J.P. Brown, C.C. Johnston Jr, R. Lang, M.R. McClung, L.E. Mallette, P.D. Miller, W.G. Ryan, F.R. Singer, J.R. Tucci, R.A. Eusebio, and P.J. Bekker. 1998. Risedronate in the treatment of Paget\u2019s disease of bone: an open label, multicenter study. Journal of Bone and Mineral Research 13: 1032\u20131038.","journal-title":"Journal of Bone and Mineral Research"},{"key":"297_CR38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00198-012-2179-3","volume":"24","author":"J Yates","year":"2013","unstructured":"Yates, J. 2013. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporosis International 24: 253\u2013262.","journal-title":"Osteoporosis International"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-013-0297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12272-013-0297-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-013-0297-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T21:13:47Z","timestamp":1746047627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12272-013-0297-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1007\/s12272-013-0297-x","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]}}}